• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Palatin Technologies Inc. filed SEC Form 8-K: Shareholder Director Nominations

    9/6/24 4:35:29 PM ET
    $PTN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PTN alert in real time by email
    ptn_8k.htm
    0000911216false00009112162024-09-052024-09-05iso4217:USDxbrli:sharesiso4217:USDxbrli:shares

       

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

     

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934

     

    Date of Report (Date of earliest event reported): September 5, 2024

     

    Palatin Technologies, Inc.

    (Exact name of registrant as specified in its charter)

     

    Delaware

     

    001-15543

     

    95-4078884

    (State or other jurisdiction

     

    (Commission

     

    (IRS employer

    of incorporation)

     

    File Number)

     

    identification number)

     

    4B Cedar Brook Drive, Cranbury, NJ

     

    08512

    (Address of principal executive offices)

     

    (Zip Code)

     

    Registrant's telephone number, including area code: (609) 495-2200

     

    Not Applicable

    (Former name or former address, if changed since last report.)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of Each Class

     

    Trading Symbol

     

    Name of Each Exchange

    on Which Registered

    Common Stock, par value $.01 per share

     

    PTN

     

    NYSE American

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

    Item 5.08 Shareholder Director Nominations.

     

    Palatin Technologies, Inc. (the “Company”) has established December 12, 2024 as the date of the Company’s annual meeting of stockholders for the fiscal year ended June 30, 2024 (the “Annual Meeting”), and October 28, 2024 as the record date for determining stockholders entitled to notice of, and to vote at, the Annual Meeting. The time, place, and detailed information regarding the proposals to be presented at the Annual Meeting will be set forth in a Definitive Proxy Statement on Schedule 14A to be filed with the U.S. Securities and Exchange Commission.

     

    Because the date of the Annual Meeting will be more than 30 days from the anniversary of the Company’s annual meeting of stockholders for the fiscal year ended June 30, 2023 held on June 27, 2024, the deadline for submission of proposals by stockholders for inclusion in the Company’s proxy materials for the Annual Meeting, in accordance with Rule 14a-8 under the Exchange Act of 1934, as amended (the “Exchange Act”), will be October 21, 2024, which the Company has determined to be a reasonable time before it expects to begin to print and send its proxy materials. Any such proposal must also meet the requirements set forth in the rules and regulations of the Exchange Act in order to be eligible for inclusion in the proxy materials for the Annual Meeting.

     

    In addition, in accordance with the Company’s Amended and Restated Bylaws, any stockholder who intends to nominate a person for election as a director or submit a proposal for inclusion at the Company’s Annual Meeting must provide notice on or before the close of business on September 13, 2024. Such notice must comply with the specific requirements set forth in the Company’s Amended and Restated Bylaws in order to be considered at the Annual Meeting. Any such proposal shall be marked for the attention of the Secretary and mailed to our executive offices, 4B Cedar Brook Drive, Cranbury, NJ 08512.

     

     

    2

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

    PALATIN TECHNOLOGIES, INC.

     

     

     

     

     

    Date: September 6, 2024

    By:

    /s/ Stephen T. Wills

     

     

     

    Stephen T. Wills, CPA, MST

     

     

     

    Executive Vice President, Chief Financial Officer and Chief Operating Officer

     

     

     

    3

     

    Get the next $PTN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PTN

    DatePrice TargetRatingAnalyst
    12/12/2025$60.00Buy
    Laidlaw
    12/3/2025$50.00Buy
    Alliance Global Partners
    11/24/2021$2.00 → $5.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $PTN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Palatin Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update

    Significant progress on multiple fronts – obesity pipeline advancing towards the clinic, out-licensing collaboration, strengthened balance sheet, and reinstatement of NYSE American trading Melanocortin-based therapies for obesityPL7737 IND-enabling toxicology underway; IND submission and clinical trial initiation planned for the first half of 2026Next-generation selective peptide MC4R agonists designed for once-weekly subcutaneous dosing; IND submission and clinical trial initiation planned for mid-2026Research Collaboration, License and Patent Assignment Agreement with Boehringer Ingelheim for the treatment of retinal diseases in August 2025Received €2.0M ($2.3M) upfrontAchieved €5.5M ($6.5

    11/13/25 7:30:00 AM ET
    $PTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Palatin Technologies Announces Closing of Upsized $18.2 Million Public Offering with the Full Exercise of the Underwriters' Over-Allotment Option

    Trading of Palatin's common shares resumed trading on NYSE today, November 12, 2025, under the symbol "PTN" PRINCETON, N.J., Nov. 12, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE:PTN) ("Palatin" or the "Company"), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced the closing of its previously announced underwritten public offering of 2,795,384 shares of its common stock (or pre-funded warrants in lieu thereof), which included the full exercise of the underwriters' option to purchase 364,615 additional shares of common stock (or pre-funded warrants in lieu thereof).

    11/12/25 12:15:00 PM ET
    $PTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Palatin Presents Data at ObesityWeek® 2025 Highlighting Promise of Melanocortin-Based Therapies for Obesity

    Oral MC4R agonist PL7737 demonstrated robust weight loss, safety, and high oral bioavailability in preclinical modelsClinical data supports co-administration of an MC4R agonist with tirzepatide as a safe, potentially synergistic approach to weight managementPL7737 IND-enabling toxicology underway, with an IND submission and clinical trial initiation planned for the first half of 2026; clinical data expected in the second half of 2026PRINCETON, N.J., Nov. 6, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (OTCQB:PTNT), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced the presentat

    11/6/25 8:00:00 AM ET
    $PTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PTN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Laidlaw initiated coverage on Palatin Technologies with a new price target

    Laidlaw initiated coverage of Palatin Technologies with a rating of Buy and set a new price target of $60.00

    12/12/25 8:54:18 AM ET
    $PTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alliance Global Partners initiated coverage on Palatin Technologies with a new price target

    Alliance Global Partners initiated coverage of Palatin Technologies with a rating of Buy and set a new price target of $50.00

    12/3/25 7:47:15 AM ET
    $PTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HC Wainwright & Co. reiterated coverage on Palatin Technologies with a new price target

    HC Wainwright & Co. reiterated coverage of Palatin Technologies with a rating of Buy and set a new price target of $5.00 from $2.00 previously

    11/24/21 6:07:03 AM ET
    $PTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PTN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Deveer Robert K Jr bought $10,180 worth of shares (100,000 units at $0.10), increasing direct ownership by 263% to 138,065 units (SEC Form 4)

    4 - PALATIN TECHNOLOGIES INC (0000911216) (Issuer)

    5/12/25 9:30:59 PM ET
    $PTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Deveer Robert K Jr bought $12,703 worth of shares (6,000 units at $2.12), increasing direct ownership by 17% to 40,845 units (SEC Form 4)

    4 - PALATIN TECHNOLOGIES INC (0000911216) (Issuer)

    4/11/24 4:45:17 PM ET
    $PTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PTN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Spana Carl covered exercise/tax liability with 321 shares, decreasing direct ownership by 0.50% to 64,377 units (SEC Form 4)

    4 - PALATIN TECHNOLOGIES INC (0000911216) (Issuer)

    1/2/26 4:30:20 PM ET
    $PTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Executive VP and CFO/COO Wills Stephen T covered exercise/tax liability with 212 shares, decreasing direct ownership by 0.33% to 63,276 units (SEC Form 4)

    4 - PALATIN TECHNOLOGIES INC (0000911216) (Issuer)

    1/2/26 4:30:25 PM ET
    $PTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Executive VP and CFO/COO Wills Stephen T sold $9,461 worth of shares (565 units at $16.74), decreasing direct ownership by 0.88% to 63,488 units (SEC Form 4)

    4 - PALATIN TECHNOLOGIES INC (0000911216) (Issuer)

    12/29/25 4:30:13 PM ET
    $PTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PTN
    Financials

    Live finance-specific insights

    View All

    Palatin Reports Second Quarter Fiscal Year 2025 Financial Results and Provides Business Update

    Phase 2 obesity co-administration study with MC4R agonist bremelanotide plus GLP-1/GIP dual agonist tirzepatideDatabase lock completedTopline data readout expected later this monthNovel 'next generation' selective MC4R long-acting peptide and an oral small moleculeMultiple clinical trials targeted in calendar year 2025For the treatment of general obesity, weight loss management, and rare MC4R pathway diseases, including hypothalamic obesityPhase 2 clinical study of PL8177 oral formulation for the treatment of ulcerative colitis Topline data readout expected later this quarterTeleconference and Webcast to be held on February 13, 2025, at 11:00 AM ETCRANBURY, N.J., Feb. 13, 2025 /PRNewswire/ -

    2/13/25 7:30:00 AM ET
    $PTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Palatin to Report Second Quarter Fiscal Year 2025 Results; Teleconference and Webcast to be held on February 13, 2025

    CRANBURY, N.J., Feb. 10, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE:PTN) will announce its second quarter fiscal year 2025 operating results on Thursday, February 13, 2025, before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on February 13, 2025, at 11:00 a.m. ET. The conference call will include a review of the company's operating results and an update on programs under development. Schedule for the Operating Results Press Release, Conference Call / Audio Webcast Q

    2/10/25 4:00:00 PM ET
    $PTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Palatin Reports First Quarter Fiscal Year 2025 Operating/Financial Results

    Obesity programs:Core focus on obesity includes exploratory co-administration BMT-801 study and two novel development drug candidatesPhase 2 BMT-801 clinical study with MC4R agonist bremelanotide plus GLP-1/GIP dual agonist tirzepatidePatient enrollment completed October 2024Topline results expected 1Q calendar year 2025Multiple clinical trials targeted in calendar year 2025 with long-acting MC4R peptide and oral small molecule compoundsGeneral obesity, weight loss management, and rare MC4R pathway diseases like hypothalamic obesityDry eye disease (DED) and other ocular programs, ulcerative colitis (UC), male sexual dysfunction, and diabetic nephropathy programs:Investment bank engaged as a

    11/14/24 7:30:00 AM ET
    $PTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PTN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Palatin Technologies Inc. (Amendment)

    SC 13G/A - PALATIN TECHNOLOGIES INC (0000911216) (Subject)

    2/14/24 2:55:16 PM ET
    $PTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Palatin Technologies Inc.

    SC 13G - PALATIN TECHNOLOGIES INC (0000911216) (Subject)

    2/14/23 1:19:39 PM ET
    $PTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PTN
    SEC Filings

    View All

    Amendment: Palatin Technologies Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K/A - PALATIN TECHNOLOGIES INC (0000911216) (Filer)

    12/19/25 4:30:47 PM ET
    $PTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Palatin Technologies Inc.

    10-Q - PALATIN TECHNOLOGIES INC (0000911216) (Filer)

    5/14/25 5:00:30 PM ET
    $PTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B4 filed by Palatin Technologies Inc.

    424B4 - PALATIN TECHNOLOGIES INC (0000911216) (Filer)

    5/8/25 5:27:16 PM ET
    $PTN
    Biotechnology: Pharmaceutical Preparations
    Health Care